Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, gives an update on antibody-based treatment approaches for patients with multiple myeloma. Monoclonal antibodies such as daratumumab and isatuximab have been approved for the treatment of relapsed myeloma for several years. Recent data from ASH on the GRIFFIN (NCT02874742) and GMMG HD7 (NCT03617731) trials are showing promising results for these two drugs in quadruplet regimens in the frontline setting. Bispecific antibodies are another exciting area of research in multiple myeloma, with agents including teclistamab, talquetamab, and cevostamab, who have been shown to induce response rates (RRs) averaging 60-70% in heavily pre-treated populations, and are associated with less frequent and less severe side effects than chimeric antigen receptor (CAR) T-cell therapy. These agents are expected to be approved in the upcoming years, which will broaden the therapeutic landscape for heavily pre-treated patients with multiple myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.